Quantcast
Last updated on April 17, 2014 at 7:47 EDT

Latest liver cirrhosis Stories

2014-04-14 12:51:21

The new interferon-free, all-oral, three direct-acting-antiviral (3D) treatment regimen in development by AbbVie has achieved very high rates of virological response in patients chronically infected with hepatitis C virus (HCV) genotype 1 (GT1); according to the results of three studies presented today at the International Liver CongressTM 2014. The 3D regimen consists of the HCV NS3/4A protease inhibitor ABT-450 dosed with ritonavir, the NS5A inhibitor ABT-267, and the NS5B RNA polymerase...

2014-03-13 23:26:09

Liver Cirrhosis Bible & Ezra Protocol, created by Debrea Elkin, is a brand new product that uncovers useful tips on how to cure liver cirrhosis disease. The site Vkool.com published an entire Liver Cirrhosis Bible & Ezra Protocol review, showing readers if this product is worth purchasing. Seattle, Wa (PRWEB) March 13, 2014 Liver cirrhosis is a very common condition in the world, especially in developing countries. It is a result of advanced liver disease. Liver Cirrhosis Bible...

2013-06-27 23:52:11

Liver Cirrhosis Bible developed by Debra Elkin is a new cirrhosis treatment book that gives people natural remedies, safe methods, simple exercises, and detailed instructions on how to cure their cirrhosis fast. A full Liver Cirrhosis Bible overview on the site Vkool.com indicates if the book is worth buying. Seattle, Wa (PRWEB) June 26, 2013 Liver Cirrhosis Bible is a new cirrhosis treatment book that gives people natural remedies, safe methods, simple exercises, and detailed...

2013-03-14 17:26:28

According to WHO, liver cirrhosis accounts for 1.8% (i.e. 170,000) of all deaths in Europe. In recent years liver cirrhosis has become a serious health threat in some Western European countries such as Ireland and the United Kingdom, where over the last 10 years the associated mortality has increased . The European Association for the Study of the Liver (EASL) urges the UK government to press ahead with its proposed implementation of the minimum unit pricing of alcohol. EASL's most recent...

2012-07-03 06:25:06

SHENZHEN, China, July 3, 2012 /PRNewswire-Asia/ -- A study conducted by Beike Biotechnology Company (http://www.beikebiotech.com) in conjunction with physicians and researchers at two Chinese hospitals, documents the effectiveness of cord blood-derived stem cells in treating primary biliary cirrhosis (PBC). The study, which was published in the April 2012 issue of the Stem Cell Discovery, was the first of its kind. Researchers noted that additional clinical trials would be required before...

2012-05-29 02:26:48

BARCELONA, Spain and SAN DIEGO, May 29, 2012 /PRNewswire/ --- Hospital Universitari Vall d'Hebron Research Institute in Barcelona and Ocera Therapeutics, Inc. announced today preliminary data from an open label phase 2 study evaluating the overall effectiveness and safety of OCR-002 (ornithine phenylacetate) for the treatment of cirrhosis of the liver and upper GI bleeding. An interim analysis of the first cohort of patients demonstrated that OCR-002 is well tolerated and provided a rapid and...

2011-07-13 00:00:00

ZURICH, Switzerland, July 13, 2011 /PRNewswire/ -- New Technology Expands Treatment Options for Patient With Refractory Ascites Due to Liver Cirrhosis. Dr. Farzana Malik Joins as Vice President of Market Access and Reimbursement. Sequana Medical announced today that it has received CE Mark approval for the commercial sale of its ALFApump(TM) System. Over the coming months, the company will launch the product in selected hepatology and liver transplant hospitals across...

2010-04-16 06:00:00

VIENNA, April 16 /PRNewswire/ -- Ocera Therapeutics, Inc. presented an analysis of the prevalence of neurocognitive impairment in ambulatory cirrhotic patients. The data came from the screening period of the ASTUTE Study, an ongoing Phase 2b study evaluating the safety and efficacy of AST-120 (spherical carbon adsorbent) in the treatment of mild hepatic encephalopathy (MHE). The poster was presented yesterday at the annual meeting of the European Association for the Study of Liver (EASL)...

2010-02-23 14:12:00

SAN DIEGO, Feb. 23 /PRNewswire/ -- Ocera Therapeutics, Inc. announced today that the ASTUTE Study (AST-120 Used to Treat Hepatic Encephalopathy) has completed enrollment for its Phase 2B study ahead of schedule, with data expected mid 2010. AST-120 adsorbs ammonia and other gut derived toxins that factor prominently in the underlying cause of mild hepatic encephalopathy (MHE), a neurocognitive disorder present in a majority of patients with cirrhosis of the liver. Because MHE leads to a...

2010-02-10 09:10:21

Hepatitis B virus (HBV) genotypes have distinct geographical distributions, and have been shown to differ with regard to clinical outcome and prognosis. However, the relationship between HBV genotypes and liver cirrhosis remains controversial and no study on exploring the association between HBV genotypes and subclinical cirrhosis in community-based population has been reported. A research article to be published on January 21, 2010 in the World Journal of Gastroenterology addresses this...